Coca-Cola HBC AG (CCHBF) Research
Coca-Cola HBC AG is a worldwide bottler and seller of an extensive array of ready-to-drink beverages. Its comprehensive portfolio features carbonated soft drinks, hydrating options, fruit juices, ready-to-drink teas, energy boosters, coffee, bottled water, and plant-based drinks. The company also offers premium spirits, flavored alcoholic beverages, and snacks. It markets and sells its products under well-known brand names like Coca-Cola, Fanta, Sprite, Adez, Aquarius, Averna, Amita, Avra, Deep RiverRock, Fruice, Kinley, and Schweppes, among others. Beyond its own brands, Coca-Cola HBC AG also handles the distribution of third-party products, including Monster energy drinks and various beer brands. Its broad distribution network reaches a diverse set of retail and hospitality channels, including large supermarkets, hypermarkets, discount retailers, convenience stores, wholesalers, hotels, restaurants, cafés, and e-commerce platforms. Established in 1969, the company's corporate headquarters are located in Steinhausen, Switzerland.
Market snapshot
- Symbol
- CCHBF
- Price
- $63.02
- Day change
- +0.43%
- Market cap
- $19.1B
- P/E ratio
- 20.26x
- 52-week range
- 45.9-63.16
- Sector
- Consumer Defensive
- Industry
- Beverages - Non-Alcoholic
- Next earnings
- in 2 months
Recent news
- Coca-Cola HBC Sales Grow on Caffeine Consumption Spike
The London- and Athens-listed bottler saw 27% volume growth for its energy-drink category, and coffee volumes increased 39% in its out-of-home channel.
Peer companies
- Budweiser Brewing Company APAC Limited (BDWBF)
- Budweiser Brewing Company APAC Limited (BDWBY)
- China Resources Beer (Holdings) Company Limited (CRHKF)
- China Resources Beer (Holdings) Company Limited (CRHKY)
- CP ALL Public Company Limited (CVPBF)
- Arca Continental, S.A.B. de C.V. (EMBVF)
- Kirin Holdings Company, Limited (KNBWF)
- Molson Coors Canada Inc. (MXGBF)
Open Coca-Cola HBC AG (CCHBF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.